Statements (15)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
oral
|
| gptkbp:alsoKnownAs |
alvocidib hydrochloride
|
| gptkbp:CASNumber |
2094015-62-5
|
| gptkbp:clinicalTrialPhase |
Phase 1
|
| gptkbp:developedBy |
gptkb:Syros_Pharmaceuticals
|
| https://www.w3.org/2000/01/rdf-schema#label |
SY-5609
|
| gptkbp:intendedUse |
gptkb:cancer
|
| gptkbp:mechanismOfAction |
selective CDK7 inhibitor
|
| gptkbp:status |
investigational
|
| gptkbp:studiedBy |
solid tumors
hematologic malignancies |
| gptkbp:target |
gptkb:CDK7
|
| gptkbp:bfsParent |
gptkb:Syros_Pharmaceuticals
|
| gptkbp:bfsLayer |
8
|